123 related articles for article (PubMed ID: 11502772)
1. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study.
Ceccarelli C; Bencivelli W; Morciano D; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2001 Aug; 86(8):3512-5. PubMed ID: 11502772
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
5. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
6. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
7. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
8. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients.
Bartalena L; Martino E; Pacchiarotti A; Grasso L; Aghini-Lombardi F; Buratti L; Bambini G; Breccia M; Pinchera A
J Clin Endocrinol Metab; 1987 Apr; 64(4):849-55. PubMed ID: 3818906
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the efficacy of iodine-131 for thyroid ablation.
Comtois R; Thériault C; Del Vecchio P
J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
[TBL] [Abstract][Full Text] [Related]
11. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
Ozata M; Suzuki S; Miyamoto T; Liu RT; Fierro-Renoy F; DeGroot LJ
J Clin Endocrinol Metab; 1994 Jul; 79(1):98-105. PubMed ID: 8027262
[TBL] [Abstract][Full Text] [Related]
12. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
Doi SA; Woodhouse NJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
[TBL] [Abstract][Full Text] [Related]
13. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
14. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine.
Raymond JP; Izembart M; Marliac V; Dagousset F; Merceron RE; Vulpillat M; Vallée G
J Clin Endocrinol Metab; 1989 Jul; 69(1):186-90. PubMed ID: 2499590
[TBL] [Abstract][Full Text] [Related]
15. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy following operative and complementary treatment of thyroid cancer.
Pomorski L; Bartos M; Narebski J
Zentralbl Gynakol; 2000; 122(7):383-6. PubMed ID: 10951709
[TBL] [Abstract][Full Text] [Related]
17. Failure of low doses of 131I to ablate residual thyroid tissue following surgery for thyroid cancer.
Kuni CC; Klingensmith WC
Radiology; 1980 Dec; 137(3):773-4. PubMed ID: 7444061
[TBL] [Abstract][Full Text] [Related]
18. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
19. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
20. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
